158 related articles for article (PubMed ID: 31332154)
1. Ophthalmic biosimilars: Lessons from India.
Sharma A; Kumar N; Kuppermann BD; Francesco B; Lowenstein A
Indian J Ophthalmol; 2019 Aug; 67(8):1384-1385. PubMed ID: 31332154
[No Abstract] [Full Text] [Related]
2. Biosimilars for Retinal Diseases: An Update.
Sharma A; Kumar N; Parachuri N; Bandello F; Kuppermann BD; Loewenstein A
Am J Ophthalmol; 2021 Apr; 224():36-42. PubMed ID: 33309691
[TBL] [Abstract][Full Text] [Related]
3. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
Sheth JU; Stewart MW; Khatri M; Gupta SR; Chawla S; Rajendran A; Narayanan R
Indian J Ophthalmol; 2021 Feb; 69(2):352-356. PubMed ID: 33463590
[TBL] [Abstract][Full Text] [Related]
4. Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity.
Chandra P; Kumawat D; Tewari R; Azimeera S
Indian J Ophthalmol; 2019 Jun; 67(6):967-969. PubMed ID: 31124535
[TBL] [Abstract][Full Text] [Related]
5. The brave new world of biosimilars ('similar biologics') in India.
Jois R
Postgrad Med J; 2017 Oct; 93(1104):577-579. PubMed ID: 28546231
[No Abstract] [Full Text] [Related]
6. Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France.
Baudin F; Benzenine E; Mariet AS; Bron AM; Daien V; Korobelnik JF; Quantin C; Creuzot-Garcher C
JAMA Ophthalmol; 2018 Dec; 136(12):1352-1358. PubMed ID: 30242325
[TBL] [Abstract][Full Text] [Related]
7. Razumab -- the role of biosimilars for the treatment of retinal diseases.
Ferro Desideri L; Cutolo CA; Traverso CE; Nicolò M
Drugs Today (Barc); 2021 Aug; 57(8):499-505. PubMed ID: 34405207
[TBL] [Abstract][Full Text] [Related]
8. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
[TBL] [Abstract][Full Text] [Related]
9. Incidence of post-intravitreal anti-VEGF endophthalmitis at Thammasat University Hospital.
Kanchanaranya N; Rojdamrongratana D; Piyasoonthorn P
J Med Assoc Thai; 2015 May; 98(5):489-94. PubMed ID: 26058278
[TBL] [Abstract][Full Text] [Related]
10. Intraocular inflammation after intravitreal ranibizumab injections.
Fauser S; Schroeder S; Caramoy A; Kirchhof B; Lappas A
Acta Ophthalmol; 2011 Feb; 89(1):e98-9. PubMed ID: 20384590
[No Abstract] [Full Text] [Related]
11. Science of Biosimilars.
Harvey RD
J Oncol Pract; 2017 Sep; 13(9_suppl):17s-23s. PubMed ID: 28898589
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients.
Ng DS; Kwok AK; Chan CW; Li WW
Hong Kong Med J; 2012 Dec; 18(6):488-95. PubMed ID: 23223649
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy.
Sharma A; Kumar N; Parachuri N
JAMA Ophthalmol; 2021 Jun; 139(6):677-679. PubMed ID: 33914017
[No Abstract] [Full Text] [Related]
14. Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy-Reply.
Bressler NM
JAMA Ophthalmol; 2021 Jun; 139(6):678-679. PubMed ID: 33914021
[No Abstract] [Full Text] [Related]
15. Endophthalmitis following intravitreal anti-VEGF injections in ambulatory surgical centre facility: incidence, management and outcome.
Mithal K; Mathai A; Pathengay A; Jalali S; Relhan N; Motukupally SR; Sharma S; Das T
Br J Ophthalmol; 2013 Dec; 97(12):1609-12. PubMed ID: 24064940
[No Abstract] [Full Text] [Related]
16. Counterfeit Avastin in India: Punish the Criminals, Not the Patients.
Stewart MW; Narayanan R; Gupta V; Rosenfeld PJ; Martin DF; Chakravarthy U
Am J Ophthalmol; 2016 Oct; 170():228-231. PubMed ID: 27287822
[TBL] [Abstract][Full Text] [Related]
17. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
[TBL] [Abstract][Full Text] [Related]
18. Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.
Haddock LJ; Ramsey DJ; Young LH
Semin Ophthalmol; 2014; 29(5-6):257-62. PubMed ID: 25325851
[TBL] [Abstract][Full Text] [Related]
19. Ocular inflammation associated with antivascular endothelial growth factor treatment.
Fine HF; Despotidis GD; Prenner JL
Curr Opin Ophthalmol; 2015 May; 26(3):184-7. PubMed ID: 25822254
[TBL] [Abstract][Full Text] [Related]
20. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
